ORIC Pharmaceuticals Inc. (ORIC)
| Bid | 5.28 |
| Market Cap | 375.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -127.85M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -2.89 |
| Forward PE | -2.51 |
| Analyst | Buy |
| Ask | 5.32 |
| Volume | 339,527 |
| Avg. Volume (20D) | 1,084,065 |
| Open | 5.36 |
| Previous Close | 5.22 |
| Day's Range | 5.22 - 5.65 |
| 52-Week Range | 3.90 - 14.67 |
| Beta | 1.37 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...
Analyst Forecast
According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 278.07% from the latest price.
Stock Forecasts
21 hours ago · seekingalpha.com
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch BiotechORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd half of 2025 and a phase 3 trial to start in 2026. ORIC-944 in combination ...